Medicare expands IVIG coverage to rare neurological conditions
H.R. 1143 — Medicare IVIG Access Enhancement Act of 2025 · Filed by Adrian Smith (R-NE) · 2 cosponsors · Introduced Feb 7, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill expands Medicare coverage for in-home intravenous immune globulin (IVIG) treatment to include two additional neurological conditions—chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN)—beginning January 1, 2027. Currently, Medicare covers in-home IVIG only for primary immune deficiency diseases; this bill adds CIDP and MMN to that list and allows the Secretary of Health and Human Services to set different payment rates for the new conditions.
Why we flagged it
The bill's sole operative mechanism is to expand the list of diagnoses eligible for an existing Medicare benefit (in-home IVIG administration). It is a straightforward coverage-expansion measure with no hidden provisions or narrow carve-outs.
What the text implies
- The January 1, 2027 effective date creates a 2-year lag between enactment and coverage, potentially delaying patient access despite legislative approval.
- Section 1842(o)(8) amendment grants the Secretary discretion to set different payment rates for CIDP/MMN versus primary immune deficiency disease IVIG, which could result in lower reimbursement for the new conditions and affect provider willingness to offer the service.
- The bill does not specify whether existing CIDP/MMN patients currently receiving IVIG through other payment mechanisms (private insurance, out-of-pocket, clinical trials) will be grandfathered or must transition to the new Medicare pathway.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
Patients with CIDP and MMN gain access to a Medicare-covered treatment option that was previously unavailable to them, reducing out-of-pocket costs and expanding therapeutic access. The bill does not restrict any existing benefits or impose new costs on beneficiaries.
Who stands to gain
- IVIG manufacturers and distributors
- Home infusion therapy providers
- Specialty pharmacy networks
- Patients with CIDP and MMN (reduced out-of-pocket costs)
Named in the bill
Medicare, Social Security Act, Department of Health and Human Services, IVIG (intravenous immune globulin), CIDP (chronic inflammatory demyelinating polyneuropathy), MMN (multifocal motor neuropathy), Primary immune deficiency diseases
Where it stands
2 cosponsors: 2 Democrats.
- Feb 7, 2025 — Introduced · Congress.gov: “Introduced in House”
- Feb 7, 2025 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
1 lobbying clients named this bill on 2 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $840,000 in lobbying spend. A filing names 10 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 0% of bills with at least one filing.
Adrian Smith, the sponsor, reported $1,398,750 in PAC receipts in the 2026 cycle.
- Grifols Shared Services North America Inc — $840,000 on 2 filings
Lobbying Disclosure Act filings through Jul 17, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (1,125 characters) on Jun 8, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Dec 2025 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 17, 2026 · page rendered 2026-10-20.
“Medicare expands IVIG coverage to rare neurological conditions” QuorumCivic. https://share.quorumcivic.app/bill/119/hr1143 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.